<DOC>
	<DOCNO>NCT01565265</DOCNO>
	<brief_summary>The purpose study ass non-inferiority multidose GnRH antagonist ( cetrorelix ) regimen GnRH agonist ( triptorelin ) long protocol young infertile woman undergo ovarian stimulation Pergoveris 150 I.U./75 I.U . ( r-hFSH/ r-hLH ) ICSI treatment male infertility . To assess efficacy ovarian stimulation use either GnRH antagonist ( cetrorelix ) GnRH agonist ( triptorelin ) long protocol infertile woman good prognosis determine safety ovarian stimulation . Subsample analysis : 10 patient arm , serum sample collect daily stimulation period store frozen -70 °C . The follow hormone concentration measure later single assay batch : LH , FSH , oestradiol , progesterone , androstenedione , testosterone , inhibin A , inhibin B , AMH . Multinational , multicentre , open label , randomize , 2-arm parallel-group phase IV study . Eligible patient randomly allocate one two group : agonist group receive Decapeptyl® 0.1 mg ( triptorelin ) start mid-luteal phase natural cycle downregulation day ovulation induction . The antagonist group receive cetrorelix 0.25 mg stimulation day 6 ovulation induction . In group , Pergoveris® 150 I.U./75 I.U . ( r-hFSH/r-hLH ) use ovarian stimulation cycle day 2 ovulation induction .</brief_summary>
	<brief_title>Comparing Ovarian Stimulation Assisted Reproduction With Two Different Forms Pituitary Suppression</brief_title>
	<detailed_description>In assisted reproductive technology ( ART ) , follicular growth stimulate exogenous gonadotropin obtain multiple mature oocytes fertilization . In natural cycle , oocyte maturation ovulation trigger endogenous luteinizing hormone ( LH ) . To prevent premature surge LH subsequent premature ovulation cancellation ART cycle , gonadotropin release hormone ( GnRH ) agonist commonly use inhibit endogenous gonadotropin release leading premature ovulation luteinization . After short-term initial stimulation pituitary gland , continuous administration GnRH agonist lead downregulation GnRH receptor pituitary thus prevent synthesis release follicle-stimulating hormone ( FSH ) LH organ . Endogenous gonadotropin release may also prevent use GnRH antagonist instead GnRH agonist . During past decade , two GnRH antagonist ( cetrorelix , ganirelix ) license prevention premature LH surge ovulation ovarian hyperstimulation assist reproduction . The antagonist compete directly physiological GnRH binding pituitary GnRH receptor provide quick suppression gonadotropin release without initial flare . Compared GnRH agonist long protocol , GnRH antagonists require considerably short treatment period , less exogenous gonadotropin ovarian stimulation , associate few side effect , low risk ovarian hyperstimulation syndrome ( OHSS ) . An early meta-analysis 2002 , include first study compare GnRH agonist antagonist treatment regimen , show clinical pregnancy lower GnRH antagonist treatment . However , statistically significant difference life-birth rate probability life birth protocol , show recent review . However , GnRH agonists still routinely used infertility centre , whereas GnRH antagonist still preferentially prescribed old woman unfavourable prognosis . The equivalence protocol evaluate ovarian hyperstimulation base recombinant FSH . Another difference among protocols consists sudden blockage endogenous LH secretion cause administration GnRH antagonist , usually give follicle reach size 12 mm ( around day 6 menstrual cycle ) . At developmental stage , LH receptor present follicle participate follicular function . In woman treat long protocol , low endogenous level LH associate low pregnancy rate . At present , conflict data report regard effect either low high level LH midfollicular phase pregnancy rate , regardless whether GnRH agonists GnRH antagonist use . However , study perform recombinant FSH lack LH activity one single day measurement LH concentration serum may reflect endocrine activity LH throughout follicular development . The need presence LH follicular development demonstrate unequivocally woman suffer hypogonadotropic ovarian failure ( WHO I ) , lead development Pergoveris® 150 I.U./75 I.U . Pergoveris® 150 I.U./75 I.U . use stimulate development follicle ovary grant European marketing authorization 2007 . It consist fix combination recombinant human follicle-stimulating hormone ( r-hFSH ) recombinant human luteinizing hormone ( r-hLH ) allow administration substance single injection . So far , study perform demonstrate equivalence Pergoveris® GnRH antagonist protocol compare long protocol base GnRH agonist . The current study aim ass non-inferiority multidose GnRH antagonist treatment regimen GnRH agonist long protocol young infertile woman ( &lt; 36 year ) good prognosis undergo ovarian stimulation Pergoveris® intracytoplasmic sperm injection ( ICSI ) non-borderline male infertility . In addition , safety ovarian stimulation Pergoveris evaluate treatment regimen , especially regard incidence OHSS . The primary objective study ass non-inferiority multidose GnRH antagonist ( cetrorelix ) regimen GnRH agonist ( triptorelin ) long protocol young infertile woman undergo ovarian hyperstimulation Pergoveris® 150 I.U./75 I.U . ( r-hFSH/ r-hLH ) ICSI treatment male infertility . Non-inferiority define number mature metaphase II oocytes available ICSI . Secondary objective : - To assess efficacy ovarian stimulation Pergoveris use either GnRH antagonist ( cetrorelix ) GnRH agonist ( triptorelin ) long protocol infertile woman good prognosis respect number pregnancy achieve group . - To determine safety ovarian stimulation respect number woman suffer ovarian hyperstimulation syndrome ( OHSS ) . This clinical phase IV , multinational , multicentre study use open label , randomize , 2-arm parallel-group design . The study conduct various treatment unit Europe , include Switzerland ( 1 centre ) Israel . Eligible patient randomly assign one two treatment arm : - agonist group : r-hFSH/r-hLH 150 I.U./75 I.U . ( Pergoveris® ) daily cycle day 2 ovulation induction triptorelin 0.1 mg daily mid-luteal phase ( day 21 - 24 ) pre-ART cycle ovulation induction . - antagonist group : r-hFSH/r-hLH 150 I.U./75 I.U . ( Pergoveris® ) daily cycle day 2 ovulation induction cetrorelix 0.25 mg daily cycle day 7 ( stimulation day 6 ) ovulation induction .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Female patient young 36 year age indication ICSI : 20 35 year inclusive body mass index 19 30 kg/m2 indication ICSI due male infertility cycle length 27 32 day presence ovary rubella immunity write informed consent age &gt; 35 year pregnancy breast feed ovarian endometriosis uterine fibroid interfere endometrial proliferation sperm retrieval epididymis testis one previous ART treatment pregnancy know suspected hypersensitivity active substance clinically relevant systemic disease previous enrollment study know suspect noncompliance , drug alcohol abuse</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>ovarian hyperstimulation</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>GnRH agonist</keyword>
	<keyword>assist reproduction</keyword>
	<keyword>FSH</keyword>
	<keyword>LH</keyword>
</DOC>